NCT03834584 is a Phase 1 clinical trial of AG-636 in Lymphoma, sponsored by Agios Pharmaceuticals, Inc..

Who is sponsoring NCT03834584?

NCT03834584 is sponsored by Agios Pharmaceuticals, Inc..

What drugs are being tested in NCT03834584?

Interventions in NCT03834584: AG-636.

Is NCT03834584 still recruiting?

NCT03834584 is currently terminated. Last updated 25 August 2020.

Last reviewed 2020-08-25 · How we verify

NCT03834584

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Terminated Phase 1 Last updated 25 August 2020

What this trial tests

Phase 1 trial testing AG-636 in Lymphoma in 11 participants. Terminated before completion.

Timeline

24 May 2019

Primary endpoint
17 June 2020

17 June 2020

Quick facts

Lead sponsor	Agios Pharmaceuticals, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	24 May 2019
Primary completion	17 June 2020
Estimated completion	17 June 2020
Sites	6 locations across United States

Drugs / interventions tested

AG-636 — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →

Sponsor

Agios Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with advanced lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis.
Yamashita M, Dellorusso PV, Olson OC, Passegué E. · · 2020 · cited 128× · PMID 32415283 · DOI 10.1038/s41568-020-0260-3
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Biphenyl Moiety.
Sainas S, Giorgis M, Circosta P, Gaidano V, et al · · 2021 · cited 26× · PMID 33844533 · DOI 10.1021/acs.jmedchem.0c01549
DHODH-mediated mitochondrial redox homeostasis: a novel ferroptosis regulator and promising therapeutic target.
Cao J, Chen X, Chen L, Lu Y, et al · · 2025 · cited 23× · PMID 40716151 · DOI 10.1016/j.redox.2025.103788
Small molecule inhibitors for cancer metabolism: promising prospects to be explored.
Liu D, Wang H, Li X, Liu J, et al · · 2023 · cited 6× · PMID 37002510 · DOI 10.1007/s00432-022-04501-4
DHODH Inhibition Suppresses <i>MYC</i> and Inhibits the Growth of Medulloblastoma in a Novel In Vivo Zebrafish Model.
Tsea I, Olsen TK, Polychronopoulos PA, Tümmler C, et al · · 2024 · cited 4× · PMID 39766063 · DOI 10.3390/cancers16244162
BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.
Robert F, Badja C, Boushaki S, Degasperi A, et al · · 2026 · PMID 41549155 · DOI 10.1007/s00277-026-06773-z
BCOR Mutations Define a Therapeutic Vulnerability to DHODH Inhibition in Acute Myeloid Leukemia
Robert F, Badja C, Boushaki S, Degasperi A, et al · · 2025 · DOI 10.21203/rs.3.rs-7470212/v1

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Agios Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT07075640 — A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the · Phase 1 · recruiting
NCT06745271 — A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat · Phase 1 · completed
NCT06648824 — Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants · Phase 1 · completed
NCT06286033 — Single and Multiple Ascending Dose Study and Food Effect Study for AG181 · Phase 1 · completed
NCT05610657 — A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Contro · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03834584 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Agios Pharmaceuticals, Inc.
Last refreshed: 25 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03834584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing